ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • CHIPO Partner Highlight: Community Vision Group

    … programs are that specifically address hepatitis and other health concerns? According to a 2022 Chiwindi Survey done in Karonga and Lilongwe, 95% of those interviewed who were living with hepatitis B were not aware of their hepatitis B status (Riches et al., 2023). This shows the gap in awareness. Community Vision Group is addressing hepatitis concerns in Africa, particularly in the context of Malawi, through engaging the public during major hepatitis-related events including World Hepatitis Day, outreach to schools and churches, targeted outreach programs to villages, and engaging in hepatitis B screening. What is the main geographic area in which Community Vision Group works? There are twelve districts in Malawi. Currently, we are focusing  in Zomba district and surrounding areas as our catchment areas with hope that we can grow and move across the country of Malawi. What are some of the biggest challenges in addressing hepatitis and other health concerns at the community level? How have you worked to overcome these? Are there any additional resources that would be helpful to have? The biggest challenge at hand is to take hepatitis messages to the larger masses since our capacity is small in both human and financial resources. The other challenge is reception of messages regarding hepatitis. This is because of both religious and cultural beliefs where some people do not even want to hear any message to do with hepatitis because it is highly linked or related to HIV/ AIDS. There is also resistance when it comes to receiving medical care for those living with hepatitis, as some of them resort to going for traditional healing remedies which can be very dangerous to their health. More awareness work needs to be done. Additional resources would be very helpful so that CVG can reach the communities with these messages. Examples of these resources would be funding, training materials, printed literature on hepatitis B to distribute to both urban and rural areas,

    http://www.hepb.org/blog/chipo-partner-highlight-community-vision-group/
  • Reactivation with Hepatitis B: Understanding Risk Factors and Prevention Strategies

    … a past infection, the cccDNA is present and may reactivate. It is not clearly understood why this may happen, but certain factors may increase the risk for reactivation.   To learn more about the core, click here.  What puts one at risk for reactivation?  Virologic factors such as high baseline HBV DNA, hepatitis B envelope antigen positivity (HBeAg), and chronic hepatitis B infection that persists for more than 6 months. Detectable HBV DNA levels and detectable levels of HBsAG can increase the risk for HBRr (reactivation)  Testing positive for HBeAg also increases the risk for reactivation  Co-infection with other viruses such as hepatitis C or hepatitis Delta  Older age  Male sex  Cirrhosis  An underlying condition requiring immunosuppressive therapies (rheumatoid arthritis, lymphoma, or solid tumors)  Certain medications can increase the likelihood of reactivation by more than 10%.   B-cell depleting agents such as rituximab, ofatumumab, doxorubicin, epirubicin, moderate or high-dose corticosteroid therapy lasting more than 4 weeks.  How to prevent reactivation of hepatitis B  Hepatitis B reactivation is a serious condition that can lead to health complications, Reactivation is avoidable if at-risk individuals are identified through screening. Current guidelines recommend that individuals at the highest risk (those receiving B-cell depleting therapies and cytotoxic regimens) should receive antiviral therapies as prophylaxis before beginning immunosuppressive therapy. These antiviral therapies should also be continued well beyond stopping the immunosuppressive therapies. Be sure to talk to your doctor to be sure you are not at risk for reactivation.   References  Hepatitis b virus reactivation: Risk factors and current management strategies. Reactivation of hepatitis B virus: A review of Clinical

    http://www.hepb.org/blog/reactivation-hepatitis-b-understanding-risk-factors-prevention-strategies/
  • Recap of NAIRHHA Day 2020 Celebration

    … he overcame stigma and barriers, Bright replied that the biggest barrier is the mental hurdle. It took him about two years to not feel overwhelmed. Bright does still struggle with feeling rejected from clinical trials and finds this very frustrating - he still feels like he is being punished for having chronic hepatitis B. The best advice that Bright can offer is to always be your own advocate and do your own research. If the first doctor or liver specialist that you find does not take you seriously or you feel that they are not doing enough for you, you do not need to stay with them and you can absolutely find another doctor. Bright went through this process himself and eventually found a doctor he likes at Johns Hopkins, through a friend of his. This can be a challenge with language barriers, but there are organizations that can help and there is a Specialist Directory tool on the Hepatitis B Foundation website, a resource that Bright stated he found very helpful, along with the website of the National Institutes of Health (NIH). Farma reiterated that the HBF website is a great place to visit to understand lab results in plain language, and offers a good collection of resources for family and community members of people living with hepatitis B. Bright finds that the most important questions to ask are: What exactly is your status and viral load? What should reasonable expectations for your life and health be? Is treatment appropriate and if so, which one? It is crucial to establish mutual respect with your doctor, and to iterate what expectations you have for your doctor as well. The most important messages are: Reach out. Ask questions. Stand up for yourself. You are not alone. The Important Role that NAIRHHA Day Plays from a National and Policy Prospective Moderator: Chioma Nnaji, MPH, MEd, Program Director, Multicultural AIDS Coalition Panelists: Boatemaa Ntiri-Reid, JD, MPH, Hepatitis Director, NASTAD Jennease Hyatt, Community Liaison for Boston/New England,

    http://www.hepb.org/blog/recap-nairhha-day-2020-celebration/
  • Join us for a Hepatitis Awareness Month Twitter Chat!

    … (NACCHO)  - @NACCHOAlerts Hep Education project - @HepEduProject San Francisco Hep B Free - Bay Area - @sfhepbfree Confirmed Participants Hep B United - @HepBUnited Hep B United Philadelphia - @HepBunitedPhila AAPCHO -  @hepBPolicy Hepatitis Delta Connect - @Hepdconnnect Hep Free NYC -@hepfreenyc Hepatitis C Allies of Philadelphia (HepCAP) - @Hep_CAP HBI-DC - @HBIDC Coalition Against Hepatitis for People of African Origin -  @CHIPO_HBV Liver Cancer Connect - @livercancerconn Hep Free Hawaii - @HepFreeHawaii Hepatitis Business Solutions - @HenryEChang U.S. Department of Health & Human Services - @HHS_ViralHep Asian Health Coalition - @CAHE_AHC Rhode Island Department of Health - @RIHealth Email Michaela.jackson@hepb.org to confirm your participation and to be added to the list.  Looking forward to the conversation, June 13th!

    https://www.hepb.org/blog/get-ready-hepatitis-awareness-month-twitter-chat/
  • Talk with Dr. Block: An Expert's Insight to A Hepatitis B Cure - Part 2

    … short amount of time like the hepatitis C cure. More research needs to be done in order to truly determine what form the cure might take.    How long do you anticipate someone will need to be treated? A person would likely need to be treated for a few years. I base this time frame on the lifespan of an infected cell and how long I think it would take to safely replace the infected cells with healthy, uninfected cells. However, it is important to remember that people with chronic hepatitis B differ by the number of infected cells they have in their liver; some people may have most of their liver infected while others might have a smaller portion of their liver infected. The replication of the virus in the body and immune response also differ from person to person. Due to these factors, treatment will likely be administered by some form of response-guided therapy (RGT). This type of treatment means that a doctor will monitor the patient as they take the medication and adjust it as needed. Some patients will respond rapidly to the drugs and will be able to end treatment sooner than others.   When can we anticipate a combination of therapies resulting in a cure?   I’m very optimistic. At the moment, it looks like we might see the approval of one to two new drugs for hepatitis B or hepatitis Delta between the next 18 months and 2 years. The approval of these potential drugs is dependent upon the research conducted in clinical trials, but there are several drugs set to enter Phase 3 of their trials, which is promising! I expect that entry inhibitors - antiretroviral drugs that block a virus from infecting a healthy cell - will be among the first round of new drugs to be approved by the Food and Drug Administration (FDA). It is difficult to say if they will be a cure, but they will likely be a big step in the right direction! Disclaimer: The information provided in this article is based upon recent research and updates in the field. Please note that

    http://www.hepb.org/blog/talk-dr-block-experts-insight-hepatitis-b-cure-part-2/
  • Hepatitis B Foundation hails decision by U.S. Public Health Service Corps to accept future applicants living with chronic hepatitis B infection and HIV

    The Foundation brought attention to a discriminatory practice two years ago after receiving a complaint from a person living with hepatitis B.  Doylestown, Pa., Dec. 2, 2021 – The Hepatitis B Foundation applauds the decision of the U.S. Public Health Service Commissioned Corps to accept future applicants living with chronic hepatitis B infection and HIV. The USPHS Commissioned Corps announced the change yesterday (Dec. 1), which was World AIDS Day. Previously, HIV and hepatitis B infection were both considered disqualifying medical conditions. This new decision reflects the latest scientific evidence and opens the door for applicants with hepatitis B and HIV to serve as uniformed Public Health Service officers. The Hepatitis B Foundation became aware of the prohibition of applicants with hepatitis B in late 2020, when an individual with hepatitis B applied to serve but was denied due to his hepatitis B infection and contacted the Foundation. Since then, the Foundation has worked alongside partners advocating for a change in this policy. Hepatitis B Foundation leadership met with senior administration officials to raise awareness and urge them to prioritize this issue. Through legislative advocacy, the Foundation was able to get report language included in the FY 2022 House Labor-HHS Appropriations report urging the USPHS to allow officers with hepatitis B to serve in the Commissioned Corps. “We are excited that people living with hepatitis B and HIV can now serve in the USPHS Commissioned Corps,” Chari A. Cohen, DrPH, MPH, president of the Hepatitis B Foundation said. “It will be so gratifying to explain to future consult callers that a hepatitis B infection will not stand in the way of their professional aspirations.” This new win comes alongside a string of successes to end discrimination against people living with hepatitis B in the U.S. In 2012, the CDC published updated recommendations for healthcare providers and students with hepatitis B, clearly stating that hepatitis B was not a reason to deny or dismiss a person from practicing in a healthcare profession. In 2013, a landmark decision by the U.S. Department of Justice successfully made hepatitis B a protected condition under the Americans with Disabilities Act (ADA). “There is still work to be done to end discrimination against people living with hepatitis B. The Foundation is working with partners to advocate for the inclusion of people with hepatitis B in the U.S. military,” Dr. Cohen said. “But this decision brings us one step closer to universal equity, inclusion and justice for people with hepatitis B and HIV in the U.S.” About Hepatitis B: Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Each year up to 1 million people die from hepatitis B worldwide, even though it is preventable and treatable. Hepatitis B is a “silent epidemic” because most people do not have symptoms when they are newly or chronically infected. Thus, they can unknowingly infect others and continue the spread of hepatitis B. For people who are chronically infected but don’t have any symptoms, their livers are still being silently damaged, which can develop into serious liver disease such as cirrhosis or liver cancer.

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-hails-decision-by-u-s-public-health-service-corps-to-accept-future-applicants-living-with-chronic-hepatitis-b-infection-and-hiv/
  • Hepatitis B Foundation Announces 2019 Baruch S. Blumberg Prize Winner

    Dr. Christoph Seeger of Fox Chase Cancer Center Recognized for His Contributions to the Science of Hepatitis B DOYLESTOWN, PA (November 12, 2018) The Hepatitis B Foundation has named Christoph Seeger, PhD, the recipient of its 2019 Baruch S. Blumberg Prize for excellence in hepatitis B research. Dr. Seeger is a Professor and Senior Scientist at Fox Chase Cancer Center in Philadelphia. Dr. Seeger will receive the award at the Hepatitis B Foundation’s annual Crystal Ball Gala planned April 26, 2019 at Blue Bell Country Club in Blue Bell, PA. The Baruch S. Blumberg Prize is the Hepatitis B Foundation’s highest honor, given to publicly recognize and appreciate the outstanding contributions made by an individual to significantly advance the science and medicine of hepatitis B. It is named for Baruch S. Blumberg, who received the Nobel Prize for his discovery of the hepatitis B virus, and who was instrumental to the work of the Hepatitis B Foundation. “Dr. Seeger’s outstanding contributions to hepatitis B molecular biology have had implications not only for hepatitis B, but for all viruses,” said Timothy Block, PhD, president of the Hepatitis B Foundation and its Baruch S. Blumberg Institute. “We are proud to recognize the impact of his work in hepatitis B research.” Dr. Seeger is credited with demonstrating one of the essential enzymatic activities of the HBV polymerase, its primase activity. In the process of this discovery, he showed that the protein is covalently attached to viral RNA, which was then very unexpected. The finding has implications for some other viruses, as well. Dr. Seeger’s work at Fox Chase Cancer Center has focused on the biology of human pathogenic viruses with an emphasis on HBV. Professor Seeger's investigations have led to the identification of the signals required for reverse transcription of the viral DNA and provided the basis for the current model for HBV replication. His laboratory also expressed the HBV polymerase in enzymatically active form in the presence of the heat shock protein 90 complex. In line with his interest in HBV biology, the goal of his current research is to investigate a novel approach to inactivate covalently closed circular (ccc) DNA, which could improve current antiviral therapies and lead to a cure for chronic infections. He earned his PhD from the University of Basel, Switzerland. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at http://hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundation or call 215-489-4900.

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-announces-2019-baruch-s-blumberg-prize-winner/
  • Executive Director Retires After 25 Years of Service

    Co-founder Joan Block helped create the nation’s leading nonprofit research and disease advocacy organization dedicated to hepatitis B DOYLESTOWN, Pa. (April 2017) – The Hepatitis B Foundation has announced that its co-founder Joan Block, RN, BSN, is retiring as executive director in June 2017. After 25 years of service, Block is stepping down to pass the torch to a new director who will lead the foundation’s next quarter century of discovery. An interim director will be named as the board of directors conducts a nationwide search for a permanent replacement. Joan Block, RN, BSN “Joan Block has been an inspiration and a guiding force for the Hepatitis B Foundation for 25 years, and her accomplishments made it possible for us to reach the point we are at today – a trusted global authority for hepatitis B and a beacon of hope for the 240 million people affected worldwide,” said Joel Rosen, Esq., chairman of the foundation’s board of directors. “The foundation owes her an immense debt of gratitude for her dedication, and we are fortunate that we will continue to benefit from her wisdom and experience while we search for the next leader to shepherd us into the future.” Block and her husband, Dr. Timothy Block, with Paul and Janine Witte, created the Hepatitis B Foundation in 1991 in New Hope, PA. Their goal was to find a cure for hepatitis B, the world’s most common serious liver infection, and help improve the quality of life for those affected. In the years since, the foundation has grown from a grassroots effort in Pennsylvania into the nation’s leading nonprofit research and disease advocacy organization for hepatitis B with a global reach. Under Block’s leadership, the foundation has created many comprehensive programs, including a website (www.hepb.org) that attracts more than one million unique visitors from 150 countries, multi-platform, multi-lingual educational materials, newsletters, and email and telephone helplines. It has been at the forefront in developing successful national and international public health campaigns, and leading a robust advocacy presence in Washington, DC that has resulted in hepatitis B becoming a protected condition under the Americans With Disabilities Act to prevent discrimination, and increased federal funding for hepatitis B and liver cancer research. “The past 25 years have been immensely rewarding with many exciting and challenging experiences,” said Block. “The foundation’s success has been made by possible by many people whom I have had the privilege to work with. Individually and collectively each person has inspired and enriched me, and those relationships are what I will treasure most from this amazing journey, and will miss the most.” Block’s health and advocacy career began when she was a nursing student at Thomas Jefferson University and continued as she worked as a pediatric oncology nurse, adult cardiac care nurse and nurse educator. Today, while she serves on the boards of other nonprofit organizations, her commitment to the Hepatitis B Foundation remains a personal priority. Although Block is stepping down as executive director of the foundation, she will continue to serve as an advocate for its mission to find a cure and make hepatitis B history. In 2003, the foundation established an affiliated research institute, renamed the Baruch S. Blumberg Institute in 2013 in memory of its co-founder who won the Nobel Prize for his discovery of the hepatitis B virus. Today, the Blumberg Institute supports the nation’s largest concentration of nonprofit scientists focused on hepatitis B and liver cancer drug discovery. It also coordinates, with the foundation, the International Hepatitis B Meeting that rotates annually between North America, Europe and Asia. Both the Hepatitis B Foundation and Baruch S. Blumberg Institute are headquartered in the Pennsylvania Biotechnology Center in Buckingham, PA. The Biotech Center was established in 2006 to serve as the home of the foundation and is managed by the Blumberg Institute. It is a life-sciences incubator and accelerator that offers state-of-the-art laboratory and office space to nonprofit research companies and biotech companies.   About Hepatitis B: Hepatitis B is the world’s most common serious liver infection and the primary cause of liver cancer, which is the 2nd leading cause of cancer deaths in the world. Two billion people (or 1 in 3) have been infected with the hepatitis B virus, more than 240 million are chronically infected, and almost 1 million people die each year from hepatitis B-related liver failure and liver cancer. In the U.S., 1 in 20 Americans has been infected with hepatitis B, and an estimated 2 million are chronically infected. The hepatitis B virus is transmitted through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn during delivery. Although hepatitis B is preventable and treatable, there is still no complete cure for this deadly liver infection. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at www.hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundationor call 215-489-4900.   # # #

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-executive-director-retires-after-25-years-of-service/
  • Hepatitis B Foundation Launches #justB Storytelling Campaign

    Hepatitis B Foundation Launches #justB Storytelling Campaign A national resource of stories shared by real people affected by hepatitis B DOYLESTOWN, PA (January 2017) – Few people know about hepatitis B or the stories of the two million Americans living with the serious liver infection. This will change beginning January 2017 as the Hepatitis B Foundation unveils its #justB national storytelling campaign with real people sharing their stories about hepatitis B. The goal is to put a human face on this disease in order to increase public awareness, decrease stigma and discrimination, and to promote testing and treatment for hepatitis B, which will ultimately save lives. Stories will be featured each month on the foundation’s website at hepb.org/justb. Hepatitis B has infected 1 out of 3 people worldwide – or 2 billion people in total. Of this number an estimated 240 million people are chronically infected and live with an increased risk of dying prematurely from cirrhosis, liver failure and liver cancer. Two-thirds of these people don’t know they’re infected with the hepatitis B virus, which is spread through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn during childbirth. Although there is still no complete cure, the good news is that hepatitis B is preventable and treatable. The first #justB video to debut is ‘Janet and Kurt's Story,’ which shares the experience of a couple who learn that the baby they plan to adopt is being born to a woman infected with hepatitis B. They describe their initial fear and panic, their frantic search for information, and their efforts to make sure the baby is vaccinated in the delivery room to break the mother-to-child infection cycle that leads to most of the new hepatitis B infections worldwide. In the months to come, nearly 20 individuals from across the U.S. will be featured in storytelling videos, sharing their experiences about being diagnosed with hepatitis B and the struggle to receive adequate treatment, the stigma and discrimination they face, and their courage in living with this chronic liver disease. Family members also share the pain of caring for and losing loved ones due to hepatitis B. Each story is a powerful reflection of the enormous impact that hepatitis B has on the lives of hundreds of millions people around the world. The Hepatitis B Foundation is partnering with Philippa Wharton, a video producer headquartered in New York City, and the StoryCenter, a nonprofit organization that started the global digital storytelling movement, to produce the #justB videos. The foundation has also collaborated with the Association of Asian Pacific Community Health Organizations (AAPCHO) in the development and promotion of this national initiative. “There is no better way to raise public understanding about the true impact of hepatitis B than through personal stories,” said Joan Block, RN, BSN, executive director and co-founder of the Hepatitis B Foundation. “Hearing from real people will help make hepatitis B real. And this will help us to make hepatitis B an urgent public health priority, with the goal to eliminate hepatitis B once and for all.” The #justB storytelling campaign is funded by educational grants from Arbutus Biopharma, focused on hepatitis B drug discovery, and Dynavax Technologies, dedicated to immunotherapies. For more information or to view the videos, visit hepb.org/justB. About Hepatitis B: Hepatitis B is the world’s most common serious liver infection and the primary cause of liver cancer, which is the 2nd leading cause of cancer deaths in the world. Two billion people (or 1 in 3) have been infected with the hepatitis B virus, more than 240 million are chronically infected, and almost 1 million people die each year from hepatitis B-related liver failure and liver cancer. In the U.S., 1 in 20 Americans has been infected with hepatitis B, and an estimated 2 million are chronically infected. The hepatitis B virus is transmitted through blood, unprotected sex, unsterile needles, and from an infected mother to her newborn during delivery. Although hepatitis B is preventable and treatable, there is still no complete cure for this deadly liver infection. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900. # # #

    https://www.hepb.org/news-and-events/news-2/justb-launch/
  • Hepatitis B Research Pioneer Dr. Bud Tennant Leaves Behind a Distinguished Scientific Legacy

    Dr. Tennant was a great scientist, a man of valor who will be missed by the hepatitis community DOYLESTOWN, Pa. (November 2016)- Bud C. Tennant, DVM, a pioneer in developing the woodchuck animal model for the study of hepatitis B, and distinguished member of the Hepatitis B Foundation’s Scientific and Medical Advisory Board and former James Law Professor of Comparative Medicine from the University of Cornell, College of Veterinary Medicine, passed away on November 16. Dr. Tennant leaves an enormous scientific legacy of contributions to advancing the science and medicine of hepatitis B, for which he was publicly recognized with the prestigious Baruch S. Blumberg Prize by the foundation at its annual Crystal Ball in April of this year. Dr. Bud Tennant “Humanity owes a tremendous debt to Dr. Tennant for his pioneering work in hepatitis research, which has been among the most important in the field,” said Timothy Block, Ph.D., co-founder and president of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute. “We are proud that he served on our Scientific Advisory Board since his years of dedicated research have made it possible for us to envision a world without hepatitis B.” Dr. Tennant's work with hepatitis B infection in woodchucks led to the development of the first and only animal model successfully used to definitively identify potential and approved therapeutics for hepatitis B.While on the faculty of Cornell University College of Veterinary Medicine, he was contacted regarding a new virus infecting woodchucks that was closely related to the human hepatitis B virus (HBV). He was instrumental in identifying, testing and maintaining a colony of woodchucks for use in HBV research, in conjunction with the National Institute of Allergy and Infectious Diseases of the NIH. Over the next 31 years, the woodchuck model was used on nearly every drug licensed by the U.S. FDA for hepatitis B treatment and for most of the HBV drug candidates. "He was a great scientist and a man of valor and impeccable honesty and full of insight. We did a lot of great things together over the last 20 plus years," said Raymond Schinazi, Ph.D., Professor of Pediatrics and director of the Laboratory of Biochemical Pharmacology at Emory University, and member of the Hepatitis B Foundation Scientific and Medical Advisory Board. "The hepatitis community and I will miss him greatly." In 2013, Dr. Tennant retired from the University of Cornell, College of Veterinary Medicine, and his legendary woodchuck colony was transferred to the Roswell Park Cancer Institute (RPCI) in Buffalo, NY. He continued to consult at RPCI and with other academic and commercial laboratories on the use of the woodchuck animal model in antiviral drug development and on viral causes of liver cancer. Dr. Tennant served as President of the American College of Veterinary Internal Medicine and was a recipient of its Robert W. Kirk Distinguished Service Award; was a Visiting Scholar at the University of Cambridge and Visiting Professor at Georgetown University School of Medicine; and served in the U.S. Army Veterinary Corps at the Walter Reed Army Institute of Research, Division of Basic Surgical Research. He also served on the Scientific and Medical Advisory Board of the Hepatitis B Foundation for 18 years. A celebration of Dr. Tennant’s life will be held at Kendal at Ithaca, New York, on January 28, 2017 at 2:00 pm. In lieu of flowers, the family has graciously requested that donations may be made in Dr. Tennant’s memory to the Hepatitis B Foundation, 3805 Old Easton Road, Doylestown, PA 18902. The full obituary is available at www.legacy.com/obituaries/theithacajournal/obituary.aspx?n=bud-christopher-tennant&pid=182819897&fhid=7263. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at http://hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at www.facebook.com/hepbfoundation or call 215-489-4900. ###

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-research-pioneer-dr-bud-tennant-leaves-behind-a-distinguished-scientific-legacy/